A study from the Icahn School of Medicine at Mount Sinai shows how cancer can fool immune cells, which normally repair the body, into actually helping develop the disease.
If you are not happy with the results below please do another search
50 search results for:
AbelsonTaylor promoted former content strategist and copy supervisor Tarah Sperando to associate creative director. Sperando will oversee copy teams on assigned brands and projects, helping to implement novel creative solutions and develop new strategies for meeting client marketing goals. She will also participate in brand planning, market research, and new business development.
The U.S. Food and Drug Administration approved Blueprint Medicines’ Ayvakit (avapritinib) for the treatment of adult patients with advanced systemic mastocytosis.
Biogen’s quest to develop additional medicines for Alzheimer’s disease beyond the company’s newly approved aducanumab hit a clinical snag as the anti-tau antibody gosuranemab failed to meet endpoints in a Phase II study and was discontinued.
Washington D.C.-based global science and technology innovator Danaher announced a definitive agreement to acquire Aldevron for $9.6 billion.
The U.S. Supreme Court on June 17 rejected a Republican bid that had been backed by former President Donald Trump’s administration to invalidate Obamacare, preserving the landmark healthcare law for the third time since the ACA’s 2010 enactment.
A senior Chinese epidemiologist said the United States should be the priority in the next phase of investigations into the origin of Covid-19 after a study showed the disease could have been circulating there as early as December 2019, state media said on June 17.
Seattle-based clinical-stage biopharmaceutical company Lumen Bioscience is teaming up with Novo Nordisk to explore research and development opportunities within obesity, among other metabolic disorders.
German biotech CureVac NV said the company’s Covid-19 vaccine was only 47 percent effective in a late-stage trial, missing the study’s main goal and throwing in doubt the potential delivery of hundreds of millions of doses to the European Union.
Pfizer Inc.’s oral rheumatoid arthritis drug Xeljanz reduced death or respiratory failure in hospitalized Covid-19 patients with pneumonia in Brazil, meeting the study’s main goal.